March 11, 2024 07:23 AM EDT
Deals

Boehringer In­gel­heim inks deal for So­sei’s GPR52-tar­get­ing schiz­o­phre­nia port­fo­lio

Ayisha Sharma

News Reporter

Boehringer In­gel­heim is team­ing up with So­sei Hep­tares to ad­vance drug can­di­dates with the po­ten­tial to treat all three as­pects of schiz­o­phre­nia in a deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times